



Congenital Dyserythropoietic Anemia Type II: High Prevalence of c.1385A>G, (p.Tyr462Cys) Mutation in the Indian Population

Arati Nandan Saptarshi¹ · Tejashree A. More¹ · Rashmi Dongerdiye¹ · Prabhakar Kedar¹

Received: 13 April 2023 / Accepted: 3 May 2023 / Published online: 19 May 2023
© The Author(s), under exclusive licence to Dr. K C Chaudhuri Foundation 2023

To the Editor: Congenital dyserythropoietic anemia (CDA) type II is the most common among other types of CDAs. It is inherited in an autosomal recessive pattern and caused due to mutations in the *SEC23B* gene [1]. Patients show moderate to severe anemia, variable transfusion requirement, icterus, pallor, hepatosplenomegaly, morphological abnormalities in the bone marrow. The gold standard for diagnosis is light and electron microscopic observation of bone marrow [2]. The molecular characterization gives a confirmed diagnosis. There are many reports of CDAII globally. However, only a few patients have been reported in the Indian population based on bone marrow morphological analysis [3].

The objective of this study was to investigate the cause of severe anemia, hepatosplenomegaly, icterus, recurrent jaundice in reference to CDA. The identification of mutation causing CDAII was performed using targeted next-generation sequencing, Sanger sequencing, and rapid detection using newly developed high-resolution melting (HRM) curve analysis. Sequence-related melt curves are generated using HRM and difference plots generated with the help of melt curves can reveal differences in the genotype [4]. We have standardized the use of HRM for the detection of common mutations causing CDAII in the Indian population. This assay was performed using Applied Biosystems StepOne™ Real-Time PCR System.

Twelve CDAII patients were identified with anemia, icterus, pallor, hepatosplenomegaly and indirect hyperbilirubinemia. Sanger sequencing showed c.1385 A>G, p. Tyr462Cys mutation in all patients. A difference plot using HRM analysis showed a prominent peak of homozygous mutation p.Tyr462Cys in patients and heterozygous mutation in parents. We describe the high prevalence of

c.1385 A>G mutation in the *SEC23B* gene in Indian CDAII patients. The application of HRM analysis for the identification of p.Tyr462Cys is a very simple, accurate, and cost-effective method for screening this mutation in the Indian population. The introduction of this technique is likely to impact on studying the prevalence of CDA.

Funding This study was performed with the financial support of the Indian Council of Medical Research New Delhi (ICMR Project NO. 54/2/2020-HUM/BMS). The funding body played no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Declarations

Consent for Publication We obtained written informed consent to identify images or other personal or clinical details from all the participants. In the case of a minor, we obtained written informed consent for publications identifying pictures or additional clinical information from the parents or legal guardians.

Conflict of Interest None.

References

1. Bianchi P, Fermo E, Vercellati C, et al. Congenital dyserythropoietic anemia type II (CDAII) is caused by mutations in the *SEC23B* gene. *Hum Mutat.* 2009;30:1292–8.
2. Heimpel H, Kellermann K, Neuschwander N, Högel J, Schwarz K. The morphological diagnosis of congenital dyserythropoietic anemia: Results of a quantitative analysis of peripheral blood and bone marrow cells. *Haematologica.* 2010;95:1034.
3. Marwaha RK, Bansal D, Trehan A, Garewal G, Marwaha N. Congenital dyserythropoietic anemia: Clinical and hematological profile. *Indian Pediatr.* 2003;40:551–5.
4. Erali M, Wittwer CT. High-resolution melting analysis for gene scanning. *Methods.* 2010;50:250–61.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

✉ Prabhakar Kedar
kedarps2002@yahoo.com

¹ Department of Hematogenetics, ICMR-National Institute of Immunohematology, Indian Council of Medical Research, 13th Floor, New Multi-storeyed Building, King Edward Memorial (KEM.) Hospital Campus, Parel, Mumbai 400012, India